US 11,925,688 B2
Compositions and methods relating to salts of specialized pro-resolving mediators
Frank C. Sciavolino, Waterford, CT (US); Gary Mathias, Ridgefield, CT (US); Michael C. Van Zandt, Guilford, CT (US); Gunnar Erik Jagdmann, Jr., Branford, CT (US); and Jessica J. Dworak, Middletown, CT (US)
Assigned to Thetis Pharmaceuticals LLC, Ridgefield, CT (US)
Filed by Thetis Pharmaceuticals LLC, Ridgefield, CT (US)
Filed on Oct. 1, 2021, as Appl. No. 17/449,685.
Application 17/449,685 is a continuation of application No. 16/535,754, filed on Aug. 8, 2019, granted, now 11,135,298.
Application 16/535,754 is a continuation of application No. 15/824,606, filed on Nov. 28, 2017, granted, now 10,420,843, issued on Sep. 24, 2019.
Application 15/824,606 is a continuation in part of application No. 15/535,936, granted, now 10,130,719, issued on Nov. 20, 2018, previously published as PCT/US2017/035752, filed on Jun. 2, 2017.
Claims priority of provisional application 62/345,043, filed on Jun. 3, 2016.
Prior Publication US 2022/0031851 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/54 (2017.01); A61K 31/202 (2006.01); A61K 31/232 (2006.01); A61K 38/03 (2006.01); A61K 45/06 (2006.01); A61K 47/62 (2017.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 1/06 (2006.01); A61P 1/12 (2006.01); A61P 29/00 (2006.01); C07C 59/42 (2006.01); C07C 229/26 (2006.01); C07C 237/12 (2006.01); C07C 237/22 (2006.01)
CPC A61K 47/541 (2017.08) [A61K 31/202 (2013.01); A61K 31/232 (2013.01); A61K 38/03 (2013.01); A61K 45/06 (2013.01); A61K 47/62 (2017.08); A61P 1/00 (2018.01); A61P 1/04 (2018.01); A61P 1/06 (2018.01); A61P 1/12 (2018.01); A61P 29/00 (2018.01); C07C 59/42 (2013.01); C07C 229/26 (2013.01); C07C 237/12 (2013.01); C07C 237/22 (2013.01); A61K 2800/00 (2013.01)] 14 Claims
 
1. A method for treating colon cancer in a subject in need of such treatment, the method comprising administering to the subject a pharmaceutical composition comprising a compound of Formula IV, or an enantiomer, polymorph, solvate, or hydrate thereof, and a carrier:

OG Complex Work Unit Chemistry
wherein
M is a divalent metal selected from magnesium (Mg2+), calcium (Ca2+), and zinc (Zn2+),
A and B are each an SPM molecule selected from an E series resolvin, a D series resolvin, and their aspirin-triggered counterparts,
R1 and R2 are each independently —(CH2)3—Y1, and —(CH2)4—Y2,
where Y1 and Y2 are each a basic function selected from a positively charged primary amine, a positively charged secondary amine, a positively charged tertiary amine, and a positively charged guanidine,
X1 and X2 are each independently H or CO—Z and Z is a peptide comprising 1 to 5 amino acids.